EUGENE, Ore.--(BUSINESS WIRE)--MitoSciences Inc. today announced an agreement with Roche Pharma to generate mitochondrial toxicity profiles for over 100 known kinase inhibitors. Under the agreement Roche will provide the compound library plus previously-gathered data from in vivo and in vitro experiments, and MitoSciences will apply its MitoTox™ technology to provide in vitro data for a broad set of mitochondrial toxicity endpoints.
